BOEHRINGER-INGELHEIM
3.8.2022 12:07:11 CEST | Business Wire | Press release
Boehringer Ingelheim, a leading research-driven biopharmaceutical company, continued to increase its supply of medicine to patients in the first half of 2022, as it expanded its research pipeline in an increasingly challenging economic, political and regulatory environment.
Boehringer Ingelheim has experienced strong momentum through greater investment in Research & Development (R&D), accelerated development of its pipeline and business development opportunities. The company also closed 11 R&D partnership and license deals so far this year, with a focus on new modalities such as protein degraders, antimicrobial resistance, regenerative medicine, oncology and data science.
Fueled by ongoing strong demand for the company’s human heart failure, diabetes and respiratory treatments, and its products for pets, currency-adjusted net sales rose by 9.5 percent to 11.2 billion EUR.
“Despite a volatile economic environment, we were able to supply more patients with the treatments that make a difference to them, while advancing our pipeline in Human Pharma as well as in Animal Health striving to transform lives where medical need is high,” said Hubertus von Baumbach, Chairman of the Board of Managing Directors.
Boehringer Ingelheim has earmarked 25 billion EUR for investments in R&D and an additional 7 billion EUR for new production technologies over the next five years. The company anticipates running eight active human medicines registrational trials by the end of the year, with the potential of bringing 15 new products to patients by 2027.
“Although we expect economic uncertainties to persist in the second half of the year, we remain confident that we can achieve our goals for 2022 and proceed on our innovation-driven path,” said Michael Schmelmer, Member of the Board of Managing Directors, responsible for Finance & Group Functions. “We will continue to focus on and invest in our most promising assets to bring the best value to patients.”
Net sales in Human Pharma were up 11.8 percent (currency-adjusted) during the first six months of 2022 at 8.4 billion EUR, mainly driven by diabetes treatment of the JARDIANCE® family at 2.5 billion EUR and the respiratory medicine OFEV® at 1.5 billion EUR.
Growth in the Animal Health business amounted to 1.2 percent (currency-adjusted) to 2.4 billion EUR. The business was impacted by challenging market conditions including inflation, COVID-19 lockdowns, outbreaks of African Swine Fever and supply chain constraints. Net sales of NEXGARD® , a parasiticide for dogs, increased 13.7 percent (currency-adjusted) to 593 million EUR, while HEARTGARD® , which prevents heartworm disease in dogs, rose 4.4 percent to 197 million EUR.
For the remainder of the year Boehringer Ingelheim is anticipating regulatory updates for Spesolimab, a potential treatment for flares in generalized pustular psoriasis (GPP), a rare, life-threatening neutrophilic skin disease. The company will also present promising data on JARDIANCE® for the treatment of patients with chronic kidney disease. In addition, major product launches are expected for Animal Health in 2022 and 2023.
Click here for the full release: https://www.boehringer-ingelheim.com/about-us/corporate-profile/boehringer-ingelheim-2022-half-year-results
View source version on businesswire.com: https://www.businesswire.com/news/home/20220803005402/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Intuit Mailchimp Unlocks a New Era of Profitable Ecommerce Marketing with Advanced, Data-Driven Capabilities10.2.2026 14:30:00 CET | Press release
Built to deliver ROI for less cost, Mailchimp now combines unified data with powerful automation across email and messagingProduct innovations available in 185 countries and territories across North America, Latin America, EMEA and APACSMS launching in 34 new markets across EMEA including Belgium, Sweden, Denmark, Norway, Finland, Portugal, Greece, Poland and more Intuit Inc. (Nasdaq: INTU), the global financial technology platform that makes Intuit TurboTax, Credit Karma, QuickBooks, and Mailchimp, today announced a set of Mailchimp product innovations that unlock profitable growth for ecommerce businesses. Powered by the Intuit platform, the enhancements include more ways for merchants to connect their data and activate omnichannel campaigns driving up to 30x ROI for ecommerce customers1 without the added price or complexity. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260210726144/en/ Built to deliver ROI for less cost
ILiAD Biotechnologies Announces $115M Oversubscribed Series B Financing to Advance BPZE1 Pertussis Vaccine10.2.2026 14:00:00 CET | Press release
Financing round led by RA Capital ManagementProceeds to support Phase 3 development of BPZE1 with pivotal study to begin in 2026 ILiAD Biotechnologies, Inc. (ILiAD), an advanced clinical stage biotech company focused on the prevention and treatment of disease caused by Bordetella pertussis, today announced the successful closing of an oversubscribed $115 million Series B financing. The financing was led by RA Capital Management with participation from new investors Janus Henderson Investors and BNP Paribas Asset Management Alts, as well as existing investors including a multi-national pharmaceutical company and AI Life Sciences. As part of the financing, Mario Barro, Ph.D., Head of Infectious Diseases at RA Capital Management has joined ILiAD’s Board of Directors. Proceeds from the Series B financing will support the advancement of ILiAD’s next generation pertussis vaccine candidate, BPZE1. Inducing both systemic and mucosal immunity, BPZE1 is a live attenuated intranasal pertussis vac
Armis Launches Armis Centrix™for Application Security to Secure the Code that Runs Organizations10.2.2026 14:00:00 CET | Press release
Solution helps security teams reduce cyber risk exposure, operate more efficiently and streamline their security stack Armis, the cyber exposure management & security company, today announced Armis CentrixTM for Application Security, which unifies application security across an organization’s software development lifecycle. The technology helps security teams secure code as a next-generation attack vector to fortify organizations’ defenses and protect against cyber threats. “To effectively manage risk, it’s essential to get to the root cause of the problem and weed it out,” said Nadir Izrael, CTO and Co-Founder of Armis. “Code-based vulnerabilities are being embedded into organizational infrastructure, and AI-generated code is exacerbating the problem, containing exponentially more vulnerabilities when compared to code written by human developers. As enterprises embrace AI-assisted coding and drive continuous development pipelines, they need a smarter, more dynamic, and unified approac
Sam Elbeck of ExaGrid Honored as a 2026 CRN® Channel Chief10.2.2026 14:00:00 CET | Press release
ExaGrid®, the industry’s only Tiered Backup Storage solution with AI-Powered Retention Time-Lock (RTL) that includes a non-network-facing tier (creating a tiered air gap), delayed deletes and immutability for ransomware recovery,today announced that CRN®—a brand of The Channel Company—has selected Sam Elbeck, ExaGrid’s Vice President of Americas Sales and Channel Partners, for inclusion on the prestigious 2026 CRN® Channel Chiefs list. This annual recognition celebrates IT vendor and distribution executives who are shaping channel strategy and driving innovation and partnership across the industry. “It’s an honor to be named to the Channel Chiefs list again this year,” said Sam Elbeck. “We are committed to the channel and view our partners as an extension of ExaGrid. We collaborate closely on every opportunity to ensure mutual success. Our channel philosophy centers on building long-term relationships grounded in honesty, integrity, and transparency. We strive for ExaGrid to be known a
Vasion Appoints Scott Lee as Chief Product Officer to Accelerate the Impact of Intelligent Print Automation10.2.2026 14:00:00 CET | Press release
Seasoned enterprise product leader brings proven track record of scaling product organizations and driving exponential value Vasion, a leader in serverless printing and Intelligent Print Automation, today announced the appointment of Scott Lee as Chief Product Officer. Lee brings more than 25 years of C-level product and growth leadership experience transforming and scaling enterprise SaaS companies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260210803525/en/ Scott Lee joins Vasion as Chief Product Officer, bringing more than 25 years of enterprise SaaS leadership experience to accelerate the company's intelligent print automation platform and AI-ready capabilities. As Chief Product Officer at Vasion, Lee will lead product management, product design, and product operations. He will focus on expanding strong product foundations and ensuring customer value as the company scales. His extensive experience modernizing complex
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom